Compare Adecoagro SA (AGRO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adecoagro SA vs State Street SPDR S&P Biotech ETF — how do they compare? Adecoagro SA trades at $10.12 (market cap $1.39B), while State Street SPDR S&P Biotech ETF trades at $161.09. The key difference: Adecoagro SA pays a 3.08% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Adecoagro SA nearer its low. Which is the better fit depends on your goals.
| AGRO | XBI | |
|---|---|---|
Market Cap | $1.39B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $15.25 | $163.87 |
52-Week Low | $7.13 | $84.71 |
Enterprise Value | $3.42B | — |
Dividend Yield | 3.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
XBI trades at $160.81, up 0.22% for the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF has surged approximately 17% over the past month, fueled by biotech sector momentum, AI-driven drug discovery advancements, and robust M&A activity. Analyst consensus remains neutral with a single hold rating, while recent news highlights strong performance relative to broader healthcare ETFs.
Outlook: XBI offers exposure to biotech growth catalysts including M&A and innovation, but high volatility and overbought conditions pose near-term risks. Long-term potential hinges on sector stability and pipeline successes, though investors face elevated beta and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
